Safety and tolerability of high-dose ulinastatin after 2-hour intravenous infusion in adult healthy Chinese volunteers: A randomized, double-blind, placebo-controlled, ascending-dose study

• Qian Chen,

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Chaoying Hu,

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Ye Liu,

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Yun Liu,

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Wei Wang,

  Affiliation Department of Emergency, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Hongchao Zheng,

  Affiliation Department of Cardiology, Shanghai Xuhui Central Hospital& Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Lianchen Rong,

  Affiliation Clinical Development Department, Techpool Bio-pharma Company, Limited, Shanghai, China

  ⨯
• Jingying Jia,

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Shixuan Sun,

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Chen Yu,

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯
• Yan Mei Liu

  * E-mail: ymliu@shxh-centerlab.com

  Affiliation Central Laboratory, Shanghai Xuhui Central Hospital & Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China

  ⨯